Russian company Geropharm has started the first phase of clinical trials for a new ultra-long action insulin, used once a week. Using the drug weekly may enhance patient adherence and improve disease management, according to experts. Currently, no insulin medication that boasts such a high frequency of use has been registered in Russia. The longest-acting insulin available lasts for approximately 42 hours.
Clinical trials will take place at the National Medical Research Center of Endocrinology and Clinical Hospital No. 3 in the Yaroslavl Region. The preclinical trials for the two-week insulin have successfully concluded in 2023.
“The innovative insulin being developed will open up new possibilities for the treatment of diabetes, which will significantly improve the quality of life of millions of patients,” said the company’s CEO Petr Rodionov. He announced the launch of the drug on the pharmaceutical market in 2028-2029.
As part of the first stage of the study, which will last until mid-2025, 40 participants will be administered the drug for the first time to evaluate the pharmacokinetics and pharmacodynamics with a single administration. This will help determine the optimal dose of the drug for further study and ensure its maximum safety and effectiveness.
